These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 32239739)

  • 21. Two Phase 3 Trials of Adalimumab for Hidradenitis Suppurativa.
    Kimball AB; Okun MM; Williams DA; Gottlieb AB; Papp KA; Zouboulis CC; Armstrong AW; Kerdel F; Gold MH; Forman SB; Korman NJ; Giamarellos-Bourboulis EJ; Crowley JJ; Lynde C; Reguiai Z; Prens EP; Alwawi E; Mostafa NM; Pinsky B; Sundaram M; Gu Y; Carlson DM; Jemec GB
    N Engl J Med; 2016 Aug; 375(5):422-34. PubMed ID: 27518661
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adalimumab: A Review in Hidradenitis Suppurativa.
    Kim ES; Garnock-Jones KP; Keam SJ
    Am J Clin Dermatol; 2016 Oct; 17(5):545-552. PubMed ID: 27665300
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Adalimumab Treatment in Women With Moderate-to-Severe Hidradenitis Suppurativa from the Placebo-Controlled Portion of a Phase 2, Randomized, Double-Blind Study.
    Gottlieb A; Menter A; Armstrong A; Ocampo C; Gu Y; Teixeira HD
    J Drugs Dermatol; 2016 Oct; 15(10):1192-1196. PubMed ID: 27741335
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Clinical response rates, placebo response rates, and significantly associated covariates are dependent on choice of outcome measure in hidradenitis suppurativa: A post hoc analysis of PIONEER 1 and 2 individual patient data.
    Frew JW; Jiang CS; Singh N; Grand D; Navrazhina K; Vaughan R; Krueger JG
    J Am Acad Dermatol; 2020 May; 82(5):1150-1157. PubMed ID: 31881294
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Hematologic Abnormalities in Patients With Hidradenitis Suppurativa Receiving Adalimumab.
    Gunter SJ; Holcomb ZE; Lam BD; Porter ML; Kimball AB
    JAMA Dermatol; 2024 Jun; 160(6):678-681. PubMed ID: 38717768
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Long-term safety of adalimumab for patients with moderate-to-severe hidradenitis suppurativa.
    Tzanetakou V; Stergianou D; Giamarellos-Bourboulis EJ
    Expert Opin Drug Saf; 2020 Apr; 19(4):381-393. PubMed ID: 32098513
    [No Abstract]   [Full Text] [Related]  

  • 27. Twenty-four-week interim analysis from a phase 3 open-label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa.
    Morita A; Takahashi H; Ozawa K; Imafuku S; Nakama T; Takahashi K; Matsuyama T; Okubo Y; Kitamura S; Matsuda N; Zhao Y; Yokoyama M; Hayashi N; Terui T
    J Dermatol; 2019 Sep; 46(9):745-751. PubMed ID: 31282051
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A severe case of hidradenitis suppurativa with chronic anemia treated with adalimumab.
    Arakawa H; Adachi T; Kobayashi Y; Inazumi T
    J Dermatol; 2023 Jan; 50(1):e22-e23. PubMed ID: 36074661
    [No Abstract]   [Full Text] [Related]  

  • 29. NICE approval of adalimumab for moderate-to-severe hidradenitis suppurativa: the end of the beginning for hidradenitis suppurativa therapeutics?
    Ingram JR; Burton T
    Br J Dermatol; 2017 Feb; 176(2):281-282. PubMed ID: 28244073
    [No Abstract]   [Full Text] [Related]  

  • 30. Clinical experience of the use of adalimumab in the management of hidradenitis suppurativa. Comparison of response rates with Crohn disease.
    Moyano B; Clemente A; Marín-Jiménez I; Martorell A
    Actas Dermosifiliogr; 2016 Sep; 107 Suppl 2():43-50. PubMed ID: 28081769
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Model-Informed Drug Development Approach Supporting Approval of Adalimumab (HUMIRA) in Adolescent Patients with Hidradenitis Suppurativa: a Regulatory Perspective.
    Bi Y; Liu J; Wang J; Epps RE; Kettl D; Marcus K; Seo S; Zhu H; Wang Y
    AAPS J; 2019 Jul; 21(5):91. PubMed ID: 31325056
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmaceutical Benefits Scheme listing of adalimumab for hidradenitis suppurativa: Is hidradenitis suppurativa a life-changing drug or does lifestyle change the drug?
    Vekic DA; Frew JW
    Australas J Dermatol; 2018 Aug; 59(3):e243-e244. PubMed ID: 29285755
    [No Abstract]   [Full Text] [Related]  

  • 33. Paradoxical hidradenitis suppurativa to biologic agents: a case series and literature review.
    Neves JM; Cunha N; Lencastre A; Cabete J
    Int J Dermatol; 2019 Nov; 58(11):e226-e228. PubMed ID: 31290151
    [No Abstract]   [Full Text] [Related]  

  • 34. Association and management of Crohn's disease plus hidradenitis suppurativa.
    dos Santos CH; Netto PO; Kawaguchi KY; Parreira Alves JA; de Alencar Souza VP; Reverdito S
    Inflamm Bowel Dis; 2012 Apr; 18(4):E801-2. PubMed ID: 21993924
    [No Abstract]   [Full Text] [Related]  

  • 35. Is it worthy to treat hidradenitis suppurativa with adalimumab in patients with melanoma and other debilitating systemic diseases? A series of clinical dilemmas.
    Zhao CY; Fernández-Peñas P
    Australas J Dermatol; 2018 Nov; 59(4):e297-e298. PubMed ID: 29672833
    [No Abstract]   [Full Text] [Related]  

  • 36. A case paradoxical hidradenitis suppurativa with janus kinase inhibitor, literature review and pooled analysis of biological agent-induced HS.
    Shaharir SS; Jamil A; Chua SH; Arumugam M; Rosli N
    Dermatol Ther; 2020 Nov; 33(6):e14021. PubMed ID: 32677247
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two paradoxical reactions in a patient with psoriasis and psoriatic arthritis: Adalimumab-induced hidradenitis suppurativa and secukinumab-induced alopecia areata.
    Öğüt ND
    J Eur Acad Dermatol Venereol; 2023 Apr; 37(4):e468-e469. PubMed ID: 36151938
    [No Abstract]   [Full Text] [Related]  

  • 38. Adalimumab medium-term dosing strategy in moderate-to-severe hidradenitis suppurativa: integrated results from the phase III randomized placebo-controlled PIONEER trials.
    Jemec GBE; Okun MM; Forman SB; Gulliver WPF; Prens EP; Mrowietz U; Armstrong AW; Geng Z; Gu Y; Williams DA; Teixeira HD; Kimball AB
    Br J Dermatol; 2019 Nov; 181(5):967-975. PubMed ID: 30916379
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HiSCR (Hidradenitis Suppurativa Clinical Response): a novel clinical endpoint to evaluate therapeutic outcomes in patients with hidradenitis suppurativa from the placebo-controlled portion of a phase 2 adalimumab study.
    Kimball AB; Sobell JM; Zouboulis CC; Gu Y; Williams DA; Sundaram M; Teixeira HD; Jemec GB
    J Eur Acad Dermatol Venereol; 2016 Jun; 30(6):989-94. PubMed ID: 26201313
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inverse psoriasis on pre-existing hidradenitis suppurativa lesions: Reply to "A case series of tumor necrosis factor inhibitor-induced psoriasis in patients with hidradenitis suppurativa".
    Baskurt D; Dogan PE; Mericoz CA; Demirkesen C; Vural S
    Dermatol Online J; 2024 Jun; 30(3):. PubMed ID: 39090054
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.